The AAPS National Biotechnology Conference (NBC) uncovers the latest science and trends that impact today’s research and pharmaceutical markets, specifically in the areas of biologics, biotechnology ...

Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its ...

In Salt Lake City, biotech founders new and seasoned reflect on ways to ride out the industry’s challenges, such as sending ...

For $300 million upfront, Bayer is purchasing Perfuse Therapeutics to advance an eye implant for glaucoma and diabetic retinopathy, marking the company’s first pharma acquisition since 2021. After ...

Viridian Therapeutics’ elegrobart normalized the degree of eye protrusion and improved double vision in a Phase 3 study. The company plans to file for approval in the first quarter of 2027. Viridian ...

Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative ...

Facing increasing pressure from both industry and the White House, FDA Commissioner Marty Makary said the strong bad press against him is “corporate spin” and that the agency has “followed the science ...

Robert F. Kennedy Jr.’s health department has consistently touted radical transparency as being key to its mission. Recent instances—the FDA’s decision not to disclose the recipients of three ...

A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.

The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.

Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...

While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on ...